Perspective Therapeutics
CATX
27 hedge funds and large institutions have $2.25M invested in Perspective Therapeutics in 2017 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 6 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
4% more funds holding
Funds holding: 26 → 27 (+1)
0.07% less ownership
Funds ownership: 0.73% → 0.66% (-0.07%)
4% less capital invested
Capital invested by funds: $2.36M → $2.25M (-$103K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
+$22.7K |
| 2 |
CWM
Catamount Wealth Management
Westport,
Connecticut
|
+$1.98K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$171K |
| 2 |
BlackRock
New York
|
-$45.3K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$9K |
| 4 |
Bank of New York Mellon
New York
|
-$8.76K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$6.95K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Citadel Advisors
Miami,
Florida
| – | -$9K | -1,451 | Closed |
|
CATX Hedge Fund Activity: Q2 2017 in Review
27 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Perspective Therapeutics (CATX) for Q2 2017, worth a combined $2.25M — down 4.4% from $2.36M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new CATX positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 6 trimmed.
The largest buyer was Virtu KCG Holdings, opening a new position worth an estimated $22.7K. The largest seller was Vanguard Group, cutting an estimated $171K.
- 27 institutional investors held Perspective Therapeutics (CATX) as of Q2 2017, up from 26 in Q1 2017.
- Funds reported $2.25M of Perspective Therapeutics stock for Q2 2017, down 4.4% quarter-over-quarter.
- 2 funds opened new Perspective Therapeutics positions in Q2 2017 and 1 closed out, a net change of +1 holder.
- The largest Perspective Therapeutics buyer in Q2 2017 was Virtu KCG Holdings, an estimated $22.7K added.
- The largest Perspective Therapeutics seller in Q2 2017 was Vanguard Group, an estimated $171K sold.
Based on aggregated 13F filings for Q2 2017.